SynthesisPloS one2017
A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04186013 (Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review.Surgical endoscopy · 2019Pooled it
- Trial
- Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy.Investigative and clinical urology · 2018Trial
- Deep Learning-Assisted Accuracy Improvement in Bladder Cancer Staging of Spectrum-Aided Visual Enhanced Cystoscopy Images.Biosensors · 2026Article
- Enhanced Endoscopic Imaging Technologies in Upper Urinary Tract Urothelial Tumors: Implications for Kidney-Sparing Surgery-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- New Trends and Future Perspectives in the Diagnosis of Urothelial Carcinoma: A Comprehensive Review of the Literature.Medicina (Kaunas, Lithuania) · 2025Review
- Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence.Nature reviews. Urology · 2025Review
- Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.International journal of biological sciences · 2025Review
- Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature.Research and reports in urology · 2025Review
- Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades.Asian journal of urology · 2024Review
- Review
- Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.International journal of molecular sciences · 2023Review
- Transurethral Resection of Bladder Tumor: Novel Techniques in a New Era.Bladder (San Francisco, Calif.) · 2023Review
- Advances in Diagnosis and Therapy for Bladder Cancer.Cancers · 2022Review
- Does Artificial Intelligence Meaningfully Enhance Cystoscopy?Journal of the National Cancer Institute · 2022Article
- Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.Frontiers in surgery · 2022Review
- Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.BMC urology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the additional detection rate (ADR) of within-patient comparisons of Narrow band imaging (NBI) and white light cystoscopy (WLC) for non-muscle invasive bladder cancer (NMIBC) detection and compare the impact of NBI and WLC on bladder cancer recurrence risk.
methodsWe searched relevant studies from PubMed, Embase, Medline, Web of Science and the Cochrane Library database for all articles in English published beforeJuly26th, 2016. Pooled ADR, diagnostic accuracy, relative risk (RR) and their 95% confidence intervals (CIs) were calculated.
resultsTwenty-five studies including 17 full texts and eight meeting abstracts were included for analysis. Compared to WLC, pooled ADR of NBI for NMIBC diagnosis was 9.9% (95% CI: 0.05-0.14) and 18.6% (95% CI: 0.15-0.25) in per-patient and per-lesion analysis, respectively. Pooled ADR of NBI for carcinoma in situ (CIS) diagnosis was 25.1% (95% CI: 0.09-0.42) and 31.1% (95% CI: 0.24-0.39) for per-patient and per-lesion analyses, respectively. The pooled sensitivity of NBI was significantly higher than WLC both at the per-patient (95.8% vs. 81.6%) and per-lesion levels (94.8% vs. 72.4%). In addition, NBI significantly reduced the recurrence rate of bladder cancer with a pooled RR value of 0.43 (95% CI: 0.23-0.79) and0.81 (95% CI: 0.69-0.95) at month three and twelve, respectively.
conclusionsNBI is a valid technique that improves the diagnosis of NMIBC and CIS compared to standard WLC either at per-patient or per-lesion level. It can reduce the recurrence rate of bladder cancer accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.